HOME >> MEDICINE >> NEWS
Cranberry juice may reduce risk of female urinary tract infections

The tangy flavor of cranberries could make life just a little sweeter for some. Drinking cranberry juice on a regular basis may help prevent urinary tract infections (UTIs) in some women, according to a review article in the May 15 issue of Clinical Infectious Diseases, now available online.

Cranberries contain two compounds that keep infection-causing bacteria from adhering to the lining of the urinary tract. Whether provided in juice or tablet form, the contents of the berries have been the subject of clinical study since 1966 in association with urinary tract infections and bacteriuria (the existence of bacteria in the urine). The review noted, however, that limitations in many of the studies conducted, such as small size, short duration, or use of a wide variety of cranberry products and dosing levels, make the results difficult to assess and compare.

The group most likely to reap benefits from regular doses of cranberry juice or tablets is sexually active adult women with recurring UTIs, who may experience a 50 percent drop in infection rates, according to some findings. Cranberry juice's value in treating already-established cases of UTI is unknown, as most studies have focused on its ability to prevent infection.

The appeal of cranberry juice as a potential preventative of UTI lies not just in its taste and familiarity, though, according to lead author Dr. Raul Raz of Haemek Medical Center in Afula, Israel. "It is a natural tendency to take 'natural products' instead of antibiotics, not only for UTI. I believe that if good clinical studies are conducted showing a beneficial effect of cranberries in UTI, physicians will also recommend using it," Dr. Raz said.

If more controlled studies of cranberries' effect on UTI do take place, Dr. Raz believes they should be varied. "In general, we need more clinical studies with different population groups, different dosages, and comparison between juice and capsules," he said.
'"/>

Contact: Jeff Minerd
jminerd@idsociety.org
703-299-0412
Infectious Diseases Society of America
28-Apr-2004


Page: 1 2

Related medicine news :

1. Cranberry component linked to reduced stroke damage
2. Grapefruit juice and medication can be a dangerous mix
3. Orange juice fortified with plant sterols found to lower bad cholesterol in healthy volunteers
4. Concord grape juice improved memory and neuro-motor skills in animal study
5. Study provides new evidence that cranberry juice may help fight heart disease
6. Colic in infants linked to inability to digest apple juice, but not white grape juice
7. Vitamin C may help juice up metabolism in older adults, offsetting weight gain
8. Glue ear could be caused by gastric juices
9. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
10. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
11. Mouse model reveals potential way to reduce cardiac deaths in kidney patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cranberry juice may reduce risk female urinary tract infections

(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: